Natural resistance to ascorbic acid induced oxidative stress is mainly mediated by catalase activity in human cancer cells and catalase-silencing sensitizes to oxidative stress

BMC Complementary and Alternative Medicine

Volumn 12, Issue , 2012, Pages

  Klingelhoeffer, Christoph ^a   Kämmerer, Ulrike ^a   Koospal, Monika ^a   Mühling, Bettina ^a   Schneider, Manuela ^a   Kapp, Michaela ^a   Kübler, Alexander ^a   Germer, Christoph Thomas ^a   Otto, Christoph ^a  

^a UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ASCORBIC ACID; CATALASE; CRYSTAL VIOLET; HYDROGEN PEROXIDE; SHORT HAIRPIN RNA;

APOPTOSIS; ARTICLE; BREAST CARCINOMA; CANCER CELL CULTURE; CANCER RESISTANCE; CANCER SUSCEPTIBILITY; CARCINOMA CELL; CELL ASSAY; CELL PROTECTION; CELL VIABILITY; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG EXPOSURE; ENZYMATIC ASSAY; ENZYME ACTIVITY; GENE SILENCING; GLIOBLASTOMA; HUMAN; HUMAN CELL; LUMINESCENCE; NUCLEOTIDE SEQUENCE; OXIDATIVE STRESS; PROTEIN EXPRESSION;

EID: 84860333654     PISSN: None     EISSN: 14726882     Source Type: Journal    
DOI: 10.1186/1472-6882-12-61     Document Type: Article

References (40)

1. Cerutti PA. Prooxidant states and tumor promotion. Science 1985, 227(4685):375-3781. 10.1126/science.2981433, 2981433.
2. Zhuang S, Yan Y, Daubert RA, Han J, Schnellmann RG. ERK promotes hydrogen peroxide-induced apoptosis through caspase-3 activation and inhibition of Akt in renal epithelial cells. Am J Physiol Renal Physiol 2007, 292(1):440-447.
3. Valko M, Leibfritz D, Moncol J, Cronin MT, Mazur M, Telser J. Free radicals and antioxidants in normal physiological functions and human disease. Int J Biochem Cell Biol 2007, 39(1):44-84. 10.1016/j.biocel.2006.07.001, 16978905.
4. Cabreiro F, Picot CR, Perichon M, Castel J, Friguet B, Petropoulos I. Overexpression of mitochondrial methionine sulfoxide reductase B2 protects leukemia cells from oxidative stress-induced cell death and protein damage. J Biol Chem 2008, 283(24):16673-16681. 10.1074/jbc.M708580200, 18424444.
5. Ho WP, Chan WP, Hsieh MS, Chen RM. Runx2-mediated bcl-2 gene expression contributes to nitric oxide protection against hydrogen peroxide-induced osteoblast apoptosis. J Cell Biochem 2009, 108(5):1084-1093. 10.1002/jcb.22338, 19746447.
6. Bram S, Froussard P, Guichard M, Jasmin C, Augery Y, Sinoussi-Barre F, Wray W. Vitamin C preferential toxicity for malignant melanoma cells. Nature 1980, 284(5757):629-631. 10.1038/284629a0, 7366735.
7. Park CH, Amare M, Savin MA, Hoogstraten B. Growth suppression of human leukemic cells in vitro by L-ascorbic acid. Cancer Res 1980, 40(4):1062-1065.
8. Leung PY, Miyashita K, Young M, Tsao CS. Cytotoxic effect of ascorbate and its derivatives on cultured malignant and nonmalignant cell lines. Anticancer Res 1993, 13(2):475-480.
9. Chen Q, Espey MG, Krishna MC, Mitchell JB, Corpe CP, Buettner GR, Shacter E, Levine M. Pharmacologic ascorbic acid concentrations selectively kill cancer cells: action as a pro-drug to deliver hydrogen peroxide to tissues. Proc Natl Acad Sci 2005, 102(38):13604-13609. 10.1073/pnas.0506390102, 1224653, 16157892.
10. Peterkofsky B, Prather W. Cytotoxicity of ascorbate and other reducing agents towards cultured fibroblasts as a result of hydrogen peroxide formation. J Cell Physiol 1977, 90(1):61-70. 10.1002/jcp.1040900109, 833212.
11. Sestili P, Brandi G, Brambilla L, Cattabeni F, Cantoni O. Hydrogen peroxide mediates the killing of U937 tumor cells elicited by pharmacologically attainable concentrations of ascorbic acid: cell death prevention by extracellular catalase or catalase from cocultured erythrocytes or fibroblasts. J Pharmacol Exp Ther 1996, 277(3):1719-1725.
12. Fisher AE, Naughton DP. Iron supplements: the quick fix with long-term consequences. Nutr J 2004, 3:2. 10.1186/1475-2891-3-2, 340385, 14728718.
13. Chen Q, Espey MG, Sun AY, Pooput C, Kirk KL, Krishna MC, Khosh DB, Drisko J, Levine M. Pharmacologic doses of ascorbate act as a prooxidant and decrease growth of aggressive tumor xenografts in mice. Proc Natl Acad Sci 2008, 105(32):11105-11109. 10.1073/pnas.0804226105, 2516281, 18678913.
14. Oberley TD, Oberley LW. Antioxidant enzyme levels in cancer. Histol Histopathol 1997, 12(2):525-535.
15. McCarty MF, Barroso-Aranda J, Contreras F. Oxidative stress therapy for solid tumors - A proposal. Med Hypotheses 2010, 74(6):1052-1054. 10.1016/j.mehy.2009.12.029, 20089364.
16. Kueng W, Silber E, Eppenberger U. Quantification of cells cultured on 96-well plates. Anal Biochem 1989, 182(1):16-19. 10.1016/0003-2697(89)90710-0, 2604040.
17. Halliwell B. Oxidative stress and cancer: have we moved forward?. Biochem J 2007, 401:1-11.
18. Motoyama S, Saito S, Inaba H, Kitamura M, Minamiya Y, Suzuki H, Saito R, Kamata S, Nakae H, Ogawa J. Red blood cells attenuate sinusoidal endothelial cell injury by scavenging xanthine oxidase-dependent hydrogen peroxide in hyperoxic perfused rat liver. Liver 2000, 20(3):200-208. 10.1034/j.1600-0676.2000.020003200.x, 10902969.
19. Savini I, Rossi A, Pierro C, Avigliano L, Catani MV. SVCT1 and SVCT2: key proteins for vitamin C uptake. Amino Acids 2008, 34:347-355. 10.1007/s00726-007-0555-7, 17541511.
20. Corpe CP, Lee JH, Kwon O, Eck P, Narayanan J, Kirk KL, Levine M. 6-Bromo-6-deoxy-L-ascorbic acid: an ascorbate analog specific for Na + -dependent vitamin C transporter but not glucose transporter pathways. J Biol Chem 2005, 280(7):5211-5220.
21. Szatrowski TP, Nathan CF. Production of large amounts of hydrogen peroxide by human tumor cells. Cancer Res 1991, 51(3):794-798.
22. Nishikawa M. Reactive oxygen species in tumor metastasis. Cancer Lett 2008, 266(1):53-59. 10.1016/j.canlet.2008.02.031, 18362051.
23. Min JY, Lim SO, Jung G. Downregulation of catalase by reactive oxygen species via hypermethylation of CpG island II on the catalase promoter. FEBS Lett 2010, 584(11):2427-2432. 10.1016/j.febslet.2010.04.048, 20416298.
24. Takeuchi T, Nakamura S, Kayasuga A, Isa S, Sato K. Multiple elements for negative regulation of the rat catalase gene expression in dedifferentiated hepatoma cells. J Biochem 2000, 128(6):1025-1031. 10.1093/oxfordjournals.jbchem.a022830, 11098146.
25. Hoffschir F, Vuillaume M, Sabatier L, Ricoul M, Daya-Grosjean L, Estrade S, Cassingena R, Calvayrac R, Sarasin A, Dutrillaux B. Decrease in catalase activity and loss of the 11p chromosome arm in the course of SV40 transformation of human fibroblasts. Carcinogenesis 1993, 14(8):1569-1572. 10.1093/carcin/14.8.1569, 8394777.
26. Xu H, Choi SM, An CS, Min YD, Kim KC, Kim KJ, Choi CH. Concentration-dependent collateral sensitivity of cisplatin-resistant gastric cancer cell sublines. Biochem Biophys Res Commun 2005, 328(2):618-622. 10.1016/j.bbrc.2005.01.015, 15694393.
27. Akman SA, Forrest G, Chu FF, Esworthy RS, Doroshow JH. Antioxidant and xenobiotic-metabolizing enzyme gene expression in doxorubicin-resistant MCF-7 breast cancer cells. Cancer Res 1990, 50(5):1397-1402.
28. Cameron E, Pauling L. Supplemental ascorbate in the supportive treatment of cancer: Prolongation of survival times in terminal human cancer. Proc Natl Acad Sci 1976, 73:3685-3689. 10.1073/pnas.73.10.3685, 431183, 1068480.
29. Cameron E, Pauling L. Supplemental ascorbate in the supportive treatment of cancer: reevaluation of prolongation of survival times in terminal human cancer. Proc Natl Acad Sci 1978, 75:4538-4542. 10.1073/pnas.75.9.4538, 336151, 279931.
30. Creagan ET, Moertel CG, O'Fallon JR, Schutt AJ, O'Connell MJ, Rubin J, Frytak S. Failure of high-dose vitamin C (ascorbic acid) therapy to benefit patients with advanced cancer.A controlled trial. N Engl J Med 1979, 301(13):687-690. 10.1056/NEJM197909273011303, 384241.
31. Moertel CG, Fleming TR, Creagan ET, Rubin J, O'Connell MJ, Ames MM. High-dose vitamin C versus placebo in the treatment of patients with advanced cancer who have had no prior chemotherapy. A randomized double-blind comparison. N Engl J Med 1985, 312(3):137-141. 10.1056/NEJM198501173120301, 3880867.
32. Riordan HD, Hunninghake RB, Riordan NH, Jackson JJ, Meng X, Taylor P, Casciari JJ, González MJ, Miranda-Massari JR, Mora EM, Rosario N, Rivera A. Intravenous ascorbic acid: protocol for its application and use. P R Health Sci J 2003, 22(3):287-290.
33. Riordan HD, Casciari JJ, González MJ, Riordan NH, Miranda-Massari JR, Taylor P, Jackson JA. A pilot clinical study of continuous intravenous ascorbate in terminal cancer patients. P R Health Sci J 2005, 24(4):269-276.
34. Renschler MF. The emerging role of reactive oxygen species in cancer therapy. Eur J Cancer 2004, 40(13):1934-1940. 10.1016/j.ejca.2004.02.031, 15315800.
35. Li C, Jackson RM. Reactive species mechanisms of cellular hypoxia-reoxygenation injury. Am J Physiol Cell Physiol 2002, 282(2):227-241.
36. Kulisz A, Chen N, Chandel NS, Shao Z, Schumacker PT. Mitochondrial ROS initiate phosphorylation of p38 MAP kinase during hypoxia in cardiomyocytes. Am J Physiol Lung Cell Mol Physiol 2002, 282(6):1324-1329.
37. Millar TM, Phan V, Tibbles LA. ROS generation in endothelial hypoxia and reoxygenation stimulates MAP kinase signaling and kinase-dependent neutrophil recruitment. Free Radic Biol Med 2007, 42(8):1165-1177. 10.1016/j.freeradbiomed.2007.01.015, 17382198.
38. Kroemer G, Pouyssegur J. Tumor cell metabolism: cancer's Achilles' heel. Cancer Cell 2008, 13(6):472-482. 10.1016/j.ccr.2008.05.005, 18538731.
39. Gao P, Zhang H, Dinavahi R, Li F, Xiang Y, Raman V, Bhujwalla ZM, Felsher DW, Cheng L, Pevsner J, Lee LA, Semenza GL, Dang CV. HIF-dependent antitumorigenic effect of antioxidants in vivo. Cancer Cell 2007, 12(3):230-238. 10.1016/j.ccr.2007.08.004, 2084208, 17785204.
40. Fang J, Seki T, Maeda H. Therapeutic strategies by modulating oxygen stress in cancer and inflammation. Adv Drug Deliv Rev 2009, 61:290-302. 10.1016/j.addr.2009.02.005, 19249331.